Pharmacogenetics of human immunodeficiency virus therapy

Phase 4

Completed

• Conditions: Topic: Infection; Subtopic: Infection (all Subtopics); Disease: Infectious diseases and microbiology; Infections and Infestations; Human immunodeficiency virus

• Registration Number: ISRCTN81110147
• Lead Sponsor: niversity of Liverpool (UK)

Brief Summary

1. 2008 results in https://www.ncbi.nlm.nih.gov/pubmed/18831695 (added 21/01/2019) 2. 2009 results in https://www.ncbi.nlm.nih.gov/pubmed/19228205 (added 21/01/2019) 3. 2010 results of population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance in https://www.ncbi.nlm.nih.gov/pubmed/20921307 (added 21/01/2019) 4. 2010 results of the effects of SNPs within OATP1A2, OATP1B1 and OATP1B3 on the pharmacokinetics of lopinavir in https://www.ncbi.nlm.nih.gov/pubmed/20051929 (added 21/01/2019) 5. 2012 results of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults in https://www.ncbi.nlm.nih.gov/pubmed/22477766 (added 21/01/2019) 6. 2012 results of the association of ABCC10 polymorphisms with nevirapine plasma concentrations in https://www.ncbi.nlm.nih.gov/pubmed/22082652 (added 21/01/2019) 7. 2014 results in https://www.ncbi.nlm.nih.gov/pubmed/24080498 (added 21/01/2019)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-05-28
• Study Completion: 2012-12-31
• Last Update Posted: 11 February 2019

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 900

Inclusion Criteria

Study A:
Recruitment from existing cohort studies

Study B:
1. Aged greater than 18 years
2. Know HIV-seropositive
3. Receiving antiretroviral therapy
4. Having drug concentration measured

Exclusion Criteria

Study A:
Recruitment from existing cohort studies

Study B:
1. Aged less than 18 years
2. Not on antiretroviral therapy

Study & Design

• Study Type: Observational
• Study Design: Not specified